Quince TherapeuticsQNCX
QNCX
About: Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
Employees: 32
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
2.45% less ownership
Funds ownership: 14.45% [Q2] → 12.0% (-2.45%) [Q3]
14% less capital invested
Capital invested by funds: $4.68M [Q2] → $4.04M (-$639K) [Q3]
21% less funds holding
Funds holding: 42 [Q2] → 33 (-9) [Q3]
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
237%
upside
Avg. target
$10
462%
upside
High target
$12
574%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Brookline Capital Kumaraguru Raja 75% 1-year accuracy 3 / 4 met price target | 406%upside $9 | Buy Initiated | 18 Dec 2024 |
D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 574%upside $12 | Buy Maintained | 14 Nov 2024 |
Maxim Group Jason McCarthy 26% 1-year accuracy 7 / 27 met price target | 237%upside $6 | Buy Initiated | 7 Nov 2024 |
Rodman & Renshaw Elemer Piros 18% 1-year accuracy 2 / 11 met price target | 518%upside $11 | Buy Initiated | 29 Oct 2024 |
EF Hutton Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 574%upside $12 | Buy Initiated | 22 Oct 2024 |
Financial journalist opinion
Neutral
Business Wire
1 month ago
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the third quarter ended September 30, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, “We are pleased to report accelerating enrollment of ou.
Neutral
Business Wire
1 month ago
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR) of data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial of the company's lead asset, EryDex.
Neutral
Business Wire
1 month ago
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation at the 53rd Child Neurology Society (CNS) Annual Meeting of safety data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial. The objective of the data analysis was to.
Neutral
Business Wire
2 months ago
Quince Therapeutics to Participate at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that management will present at three upcoming investor conferences: 2024 Maxim Healthcare Virtual Summit – Quince's Chief Executive Officer and Chief Medical Officer Dirk Thye, M.D., will participate in a fireside chat on Thursday, October 17, 2024 beginning at 3.
Neutral
Business Wire
3 months ago
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 beginning at 7 a.m. Eastern Time. A webcast of the presentation will be accessible o.
Positive
Seeking Alpha
4 months ago
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex
Quince's transformation is complete with the acquisition of EryDel in October 2023. The ongoing Phase 3 trial for the orphan disease Ataxia-Telangiectasia builds on the recently published teachings of EryDel's earlier trial. Chances for success are high, with approval and multi-billion dollar potential around the corner after topline data next year.
Neutral
Business Wire
4 months ago
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the online publication of data in The Lancet Neurology from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial evaluating the safety and efficacy of its lead asset, EryDex (dexamethasone sodium phosph.
Neutral
Business Wire
4 months ago
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the second quarter ended June 30, 2024. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, “We achieved a major clinical milestone during the second q.
Neutral
Business Wire
5 months ago
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today announced that the first patient has been dosed in the company's Phase 3 NEAT (Neurologic Effects of EryDex on Subjects with A-T) clinical trial to evaluate the neurological effects of EryDex in patients with Ataxia-Telangiectasia (A-T).
Neutral
Business Wire
6 months ago
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its EryDex System for the treatment of patients with Ataxia-Telangiectasia (A-T). EryDex is comprised of dexamethasone sodium phosphate (DS.
Charts implemented using Lightweight Charts™